NO802062L - Terapeutisk aktive, substituerte piperidiner og pyrrolidiner - Google Patents
Terapeutisk aktive, substituerte piperidiner og pyrrolidinerInfo
- Publication number
- NO802062L NO802062L NO802062A NO802062A NO802062L NO 802062 L NO802062 L NO 802062L NO 802062 A NO802062 A NO 802062A NO 802062 A NO802062 A NO 802062A NO 802062 L NO802062 L NO 802062L
- Authority
- NO
- Norway
- Prior art keywords
- formula
- compound
- methyl
- dimethylanilide
- pipecolinyl
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title description 6
- 150000003053 piperidines Chemical class 0.000 title 1
- 150000003235 pyrrolidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 39
- 238000000034 method Methods 0.000 claims abstract description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 3
- -1 pyrrolidinone carboxylic acid anilide Chemical class 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 6
- 150000004982 aromatic amines Chemical class 0.000 claims description 6
- 150000008430 aromatic amides Chemical class 0.000 claims description 5
- 150000002148 esters Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- LIJSEUXIAKMUEZ-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-n-(2-hydroxyethyl)piperidine-2-carboxamide;hydrochloride Chemical compound Cl.CC1=CC=CC(C)=C1N(CCO)C(=O)C1NCCCC1 LIJSEUXIAKMUEZ-UHFFFAOYSA-N 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical compound OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 claims description 4
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 claims description 3
- 150000008065 acid anhydrides Chemical class 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- SFGNNBCWQOIVAZ-UHFFFAOYSA-N 1h-pyrrole-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN1 SFGNNBCWQOIVAZ-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- 125000002524 organometallic group Chemical group 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 13
- 230000003444 anaesthetic effect Effects 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract description 2
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 239000003416 antiarrhythmic agent Substances 0.000 abstract 1
- 230000000699 topical effect Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 22
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 20
- 229960004194 lidocaine Drugs 0.000 description 20
- 229960002409 mepivacaine Drugs 0.000 description 18
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 18
- 239000013543 active substance Substances 0.000 description 11
- 239000003589 local anesthetic agent Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 206010003119 arrhythmia Diseases 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 9
- 206010010904 Convulsion Diseases 0.000 description 8
- 230000036461 convulsion Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 4
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 3
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 244000166550 Strophanthus gratus Species 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 229960005015 local anesthetics Drugs 0.000 description 3
- 229960003343 ouabain Drugs 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 239000005526 vasoconstrictor agent Substances 0.000 description 3
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002168 alkylating agent Substances 0.000 description 2
- 229940100198 alkylating agent Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000000936 membranestabilizing effect Effects 0.000 description 1
- NBXLEBLTPDQQJV-UHFFFAOYSA-N n-(2,6-dimethylphenyl)-1-(2-hydroxyethyl)-1-methylpiperidin-1-ium-2-carboxamide;iodide Chemical compound [I-].CC1=CC=CC(C)=C1NC(=O)C1[N+](CCO)(C)CCCC1 NBXLEBLTPDQQJV-UHFFFAOYSA-N 0.000 description 1
- MZPAQCAPWLAKSD-UHFFFAOYSA-N n-phenyl-1h-pyrrole-2-carboxamide Chemical compound C=1C=CNC=1C(=O)NC1=CC=CC=C1 MZPAQCAPWLAKSD-UHFFFAOYSA-N 0.000 description 1
- NTBKXPQLQPBJJL-UHFFFAOYSA-N n-phenylpyrrolidine-1-carboxamide Chemical compound C1CCCN1C(=O)NC1=CC=CC=C1 NTBKXPQLQPBJJL-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000563 toxic property Toxicity 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7906000A SE431092B (sv) | 1979-07-10 | 1979-07-10 | Terapeutiskt aktiva, substituerade piperidinkarboxianilider |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO802062L true NO802062L (no) | 1981-01-12 |
Family
ID=20338488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO802062A NO802062L (no) | 1979-07-10 | 1980-07-09 | Terapeutisk aktive, substituerte piperidiner og pyrrolidiner |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4302465A (de) |
| EP (1) | EP0024382B1 (de) |
| JP (1) | JPS5681561A (de) |
| AT (1) | ATE6507T1 (de) |
| AU (1) | AU538494B2 (de) |
| CA (1) | CA1162924A (de) |
| CS (1) | CS227011B2 (de) |
| DE (1) | DE3066827D1 (de) |
| DK (1) | DK290180A (de) |
| ES (1) | ES493230A0 (de) |
| FI (1) | FI802173A (de) |
| GR (1) | GR69077B (de) |
| HU (1) | HU180156B (de) |
| IL (1) | IL60390A (de) |
| NO (1) | NO802062L (de) |
| NZ (1) | NZ194284A (de) |
| PL (1) | PL125596B1 (de) |
| SE (1) | SE431092B (de) |
| ZA (1) | ZA803827B (de) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4443450A (en) * | 1982-04-15 | 1984-04-17 | Research Corporation | Platelet aggregation inhibitory agents and intermediates therefor |
| US4556664A (en) * | 1984-03-13 | 1985-12-03 | Gunnar A. K. Aberg | Method and composition for the treatment of cardiac arrhythmias |
| US4695576A (en) * | 1984-07-09 | 1987-09-22 | Astra Lake Medel Aktiebolag | L-N-n-propylpipecolic acid-2,6-xylidide |
| SE451840B (sv) * | 1986-01-03 | 1987-11-02 | Astra Laekemedel Ab | Optiskt rent monohydrat av s-(-)-1-propyl-2',6'-pipekoloxylididhydroklorid, sett att framstella denna och farmaceutiska beredningar for lokalbedovning |
| US4859685A (en) * | 1986-08-13 | 1989-08-22 | Boc, Inc. | Anesthetic composition and method of using the same |
| US5446070A (en) * | 1991-02-27 | 1995-08-29 | Nover Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5234957A (en) * | 1991-02-27 | 1993-08-10 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| US5332576A (en) * | 1991-02-27 | 1994-07-26 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
| BR0002246A (pt) * | 2000-04-06 | 2003-04-15 | Cristalia Prod Quimicos Farm | Processo de obtenção dos enantiÈmeros da bupivacaìna racêmica, processo de obtenção de composições farmacêuticas a base de levobupivacaìna: composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis e utilização das composições farmacêuticas a base de levobupivacaìna formuladas nas formas básicas ou sais farmaceuticamente aceitáveis |
| US6512120B1 (en) | 2001-03-12 | 2003-01-28 | Ortho Mcneil Pharmaceutical, Inc. | Methods for the synthesis of densely functionalized pyrrolidine intermediates |
| US7910641B2 (en) | 2001-10-12 | 2011-03-22 | Monosol Rx, Llc | PH modulated films for delivery of actives |
| US7425292B2 (en) | 2001-10-12 | 2008-09-16 | Monosol Rx, Llc | Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom |
| US11207805B2 (en) | 2001-10-12 | 2021-12-28 | Aquestive Therapeutics, Inc. | Process for manufacturing a resulting pharmaceutical film |
| US8900498B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for manufacturing a resulting multi-layer pharmaceutical film |
| US8603514B2 (en) | 2002-04-11 | 2013-12-10 | Monosol Rx, Llc | Uniform films for rapid dissolve dosage form incorporating taste-masking compositions |
| US8900497B2 (en) | 2001-10-12 | 2014-12-02 | Monosol Rx, Llc | Process for making a film having a substantially uniform distribution of components |
| US8765167B2 (en) | 2001-10-12 | 2014-07-01 | Monosol Rx, Llc | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US20190328679A1 (en) | 2001-10-12 | 2019-10-31 | Aquestive Therapeutics, Inc. | Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions |
| US10285910B2 (en) | 2001-10-12 | 2019-05-14 | Aquestive Therapeutics, Inc. | Sublingual and buccal film compositions |
| US20070281003A1 (en) | 2001-10-12 | 2007-12-06 | Fuisz Richard C | Polymer-Based Films and Drug Delivery Systems Made Therefrom |
| US8663687B2 (en) | 2001-10-12 | 2014-03-04 | Monosol Rx, Llc | Film compositions for delivery of actives |
| US7357891B2 (en) | 2001-10-12 | 2008-04-15 | Monosol Rx, Llc | Process for making an ingestible film |
| US20110033542A1 (en) | 2009-08-07 | 2011-02-10 | Monosol Rx, Llc | Sublingual and buccal film compositions |
| US7666337B2 (en) | 2002-04-11 | 2010-02-23 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| US8017150B2 (en) | 2002-04-11 | 2011-09-13 | Monosol Rx, Llc | Polyethylene oxide-based films and drug delivery systems made therefrom |
| EP1986602A2 (de) * | 2006-01-20 | 2008-11-05 | MonoSol Rx LLC | Folienverband zur verabreichung von wirkstoffen auf die schleimhaut |
| AU2007297697A1 (en) | 2006-09-20 | 2008-03-27 | Monosol Rx Llc | Edible water-soluble film containing a foam reducing flavoring agent |
| US8475832B2 (en) | 2009-08-07 | 2013-07-02 | Rb Pharmaceuticals Limited | Sublingual and buccal film compositions |
| EP2579844B1 (de) | 2010-06-10 | 2016-02-24 | Midatech Ltd. | Systeme zur freisetzung von nanopartikeln |
| US9149959B2 (en) | 2010-10-22 | 2015-10-06 | Monosol Rx, Llc | Manufacturing of small film strips |
| WO2017091739A1 (en) | 2015-11-23 | 2017-06-01 | Grace Therapeutics Llc | Topical film-forming spray |
| US11273131B2 (en) | 2016-05-05 | 2022-03-15 | Aquestive Therapeutics, Inc. | Pharmaceutical compositions with enhanced permeation |
| JP2019519487A (ja) | 2016-05-05 | 2019-07-11 | アクエスティブ セラピューティクス インコーポレイテッド | 送達増強エピネフリン組成物 |
| CN113573705A (zh) | 2018-12-19 | 2021-10-29 | 诺迪克控股公司 | 鼻内利多卡因的治疗组合物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE191322C1 (de) | 1964-01-01 | |||
| SE164063C1 (de) | 1958-07-22 | |||
| SE191321C1 (de) | 1964-01-01 | |||
| US2792399A (en) * | 1954-05-29 | 1957-05-14 | Bofors Ab | Anilides of heterocyclic compounds |
| US2799679A (en) * | 1955-04-28 | 1957-07-16 | Bofors Ab | Process of preparing amides of heterocyclic carboxylic acids |
| GB889225A (de) * | 1959-07-01 | |||
| NL6803337A (de) | 1967-03-20 | 1968-09-23 | ||
| SE7607114L (sv) * | 1976-06-22 | 1977-12-23 | Bofors Ab | Sett att framstella hydrokloriden av n-metylpiperidin-2-karbonsyra-2,6-xyllidid |
| GB1561023A (en) * | 1977-04-22 | 1980-02-13 | Beecham Group Ltd | 2-methoxy - 5 - chloro aniline derivatives |
| US4146628A (en) * | 1977-08-04 | 1979-03-27 | Edna Oppenheimer | Antiarrhythmic quinuclidine carboxylic acid xylidide and method of producing the same and similar compounds |
| DE2742582A1 (de) * | 1977-09-22 | 1979-04-05 | Hoechst Ag | Substituierte piperidinhydroxyamide, ihre herstellung und verwendung als lichtschutzmittel |
-
1979
- 1979-07-10 SE SE7906000A patent/SE431092B/sv not_active IP Right Cessation
- 1979-11-26 US US06/097,148 patent/US4302465A/en not_active Expired - Lifetime
-
1980
- 1980-06-25 IL IL60390A patent/IL60390A/xx unknown
- 1980-06-26 ZA ZA00803827A patent/ZA803827B/xx unknown
- 1980-06-27 EP EP80850106A patent/EP0024382B1/de not_active Expired
- 1980-06-27 AT AT80850106T patent/ATE6507T1/de not_active IP Right Cessation
- 1980-06-27 DE DE8080850106T patent/DE3066827D1/de not_active Expired
- 1980-07-02 AU AU60032/80A patent/AU538494B2/en not_active Ceased
- 1980-07-04 CA CA000355487A patent/CA1162924A/en not_active Expired
- 1980-07-04 DK DK290180A patent/DK290180A/da not_active Application Discontinuation
- 1980-07-07 FI FI802173A patent/FI802173A/fi not_active Application Discontinuation
- 1980-07-08 PL PL1980225542A patent/PL125596B1/pl unknown
- 1980-07-08 JP JP9232480A patent/JPS5681561A/ja active Granted
- 1980-07-09 CS CS804889A patent/CS227011B2/cs unknown
- 1980-07-09 NO NO802062A patent/NO802062L/no unknown
- 1980-07-09 HU HU80801712A patent/HU180156B/hu unknown
- 1980-07-09 NZ NZ194284A patent/NZ194284A/xx unknown
- 1980-07-09 GR GR62416A patent/GR69077B/el unknown
- 1980-07-09 ES ES493230A patent/ES493230A0/es active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| HU180156B (en) | 1983-02-28 |
| IL60390A (en) | 1984-10-31 |
| AU6003280A (en) | 1981-01-15 |
| SE7906000L (sv) | 1981-01-20 |
| DE3066827D1 (en) | 1984-04-12 |
| DK290180A (da) | 1981-01-11 |
| JPS5681561A (en) | 1981-07-03 |
| SE431092B (sv) | 1984-01-16 |
| ES8107185A1 (es) | 1981-08-16 |
| ES493230A0 (es) | 1981-08-16 |
| AU538494B2 (en) | 1984-08-16 |
| US4302465A (en) | 1981-11-24 |
| CS227011B2 (en) | 1984-04-16 |
| PL225542A1 (de) | 1981-12-23 |
| US4302465B1 (de) | 1984-01-24 |
| ZA803827B (en) | 1981-06-24 |
| EP0024382A1 (de) | 1981-03-04 |
| JPS6135178B2 (de) | 1986-08-12 |
| ATE6507T1 (de) | 1984-03-15 |
| GR69077B (de) | 1982-04-26 |
| PL125596B1 (en) | 1983-05-31 |
| CA1162924A (en) | 1984-02-28 |
| EP0024382B1 (de) | 1984-03-07 |
| FI802173A (fi) | 1981-01-11 |
| NZ194284A (en) | 1983-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO802062L (no) | Terapeutisk aktive, substituerte piperidiner og pyrrolidiner | |
| KR870000354B1 (ko) | 피리딘-2-에테르 또는 피리딘-2-티오에테르의 제조방법 | |
| US4783534A (en) | N-alkylnorscopines and acid addition salts thereof | |
| DE69023928T2 (de) | DIAMINVERBINDUNGEN UND ARZNEIMITTEL GEGEN CEREBRALE STöRUNGEN DIE DIESE ENTHALTEN. | |
| DE1595915A1 (de) | Verfahren zur Herstellung von heterocyclischen Benzamiden | |
| DE69305276T2 (de) | Arylglycinamidderivate, Verfahren zur deren Herstellung und deren Verwendung zur Therapie der Dysurie | |
| DE19933926A1 (de) | Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel | |
| US2846437A (en) | Lower alkyl 4-phenyl-1-(substituted-alkyl) piperidine-4-carboxylates and preparationthereof | |
| GB2054588A (en) | Amino-ether oxides and pharmaceutical formulations thereof | |
| DE2901170C2 (de) | ||
| DE68924751T2 (de) | Azacyclische Verbindungen, verwendbar als Arzneimittel. | |
| DE1220425B (de) | Verfahren zur Herstellung des lokalanaesthetisch wirksamen N-[1'-Benzyl-piperidyl-(4')]-naphthalin-1, 8-dicarbonsaeureimids | |
| WO2001002350A2 (de) | Neue amino- und amidosulfonamide als antivirale mittel | |
| JPH04312528A (ja) | ４−（３−トリフルオロメチルフェニル）−１，２，３，６− テトラヒドロピリジン誘導体のフリ−ラジカル捕獲剤としての使用 | |
| US3479346A (en) | N-acyl-n- (and n,n-bis-) ((1-piperidyl)-lower-alkyl)amines | |
| US2778824A (en) | Basic alkoxyalkyl esters of phenothiazine-10-carboxylic acid | |
| NO124430B (de) | ||
| SK15572000A3 (sk) | Spôsob prípravy enantiomérne čistého n-metyl-n-[(1s)-1-fenyl-2- -((3s)-s-hydroxypyrolidin-1-yl)etyl]-2,2-difenylacetamidu | |
| EP0271099A2 (de) | Substituierte Aminopropionsäureamide, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und ihre Verwendung sowie die bei der Herstellung anfallenden neuen Zwischenprodukte | |
| US2793212A (en) | Substituted benzamidopiperidinopropanes | |
| DE2119163A1 (de) | Verfahren zur Herstellung von semicyclischen Amidinen | |
| DE1543035A1 (de) | Verfahren zur Herstellung von Dibenzocycloheptenverbindungen | |
| DE1090667B (de) | Verfahren zur Herstellung von basischen Phenthiazinderivaten | |
| CH628896A5 (de) | Verfahren zur herstellung von neuen 14-substituierten vincanderivaten. | |
| CA2046527A1 (en) | 3-substituted-aminomethyl-3-substituted-oxy-17a-methyl-17a-lower-alkyl-17a-aza-d-homo-5-alpha androstanes |